Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 20522 | 395 | 30.6 | 43% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 495 | 14696 | RADIATION RESEARCH//INTERNATIONAL JOURNAL OF RADIATION BIOLOGY//AMIFOSTINE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | FRACTIONATED X IRRADIATION | Author keyword | 4 | 67% | 1% | 4 |
| 2 | RAT YOLK SAC TUMOR | Author keyword | 2 | 67% | 1% | 2 |
| 3 | DRUG EFFECT ON BRAIN | Author keyword | 1 | 100% | 1% | 2 |
| 4 | RAT YOLK SAC TUMOR CELL LINE | Author keyword | 1 | 100% | 1% | 2 |
| 5 | REGROWTH DELAY | Author keyword | 1 | 50% | 1% | 2 |
| 6 | RIF 1 MOUSE TUMOR MODEL | Author keyword | 1 | 100% | 1% | 2 |
| 7 | 1 LEUCOVORIN | Author keyword | 1 | 50% | 0% | 1 |
| 8 | BENEFITS RISKS | Author keyword | 1 | 50% | 0% | 1 |
| 9 | CISPLATINUM SENSITIVITY | Author keyword | 1 | 50% | 0% | 1 |
| 10 | HUMAN BREAST TUMOUR CELLS | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | FRACTIONATED X IRRADIATION | 4 | 67% | 1% | 4 | Search FRACTIONATED+X+IRRADIATION | Search FRACTIONATED+X+IRRADIATION |
| 2 | RAT YOLK SAC TUMOR | 2 | 67% | 1% | 2 | Search RAT+YOLK+SAC+TUMOR | Search RAT+YOLK+SAC+TUMOR |
| 3 | DRUG EFFECT ON BRAIN | 1 | 100% | 1% | 2 | Search DRUG+EFFECT+ON+BRAIN | Search DRUG+EFFECT+ON+BRAIN |
| 4 | RAT YOLK SAC TUMOR CELL LINE | 1 | 100% | 1% | 2 | Search RAT+YOLK+SAC+TUMOR+CELL+LINE | Search RAT+YOLK+SAC+TUMOR+CELL+LINE |
| 5 | REGROWTH DELAY | 1 | 50% | 1% | 2 | Search REGROWTH+DELAY | Search REGROWTH+DELAY |
| 6 | RIF 1 MOUSE TUMOR MODEL | 1 | 100% | 1% | 2 | Search RIF+1+MOUSE+TUMOR+MODEL | Search RIF+1+MOUSE+TUMOR+MODEL |
| 7 | 1 LEUCOVORIN | 1 | 50% | 0% | 1 | Search 1+LEUCOVORIN | Search 1+LEUCOVORIN |
| 8 | BENEFITS RISKS | 1 | 50% | 0% | 1 | Search BENEFITS+RISKS | Search BENEFITS+RISKS |
| 9 | CISPLATINUM SENSITIVITY | 1 | 50% | 0% | 1 | Search CISPLATINUM+SENSITIVITY | Search CISPLATINUM+SENSITIVITY |
| 10 | HUMAN BREAST TUMOUR CELLS | 1 | 50% | 0% | 1 | Search HUMAN+BREAST+TUMOUR+CELLS | Search HUMAN+BREAST+TUMOUR+CELLS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | DEPENDENT THERAPEUTIC GAIN | 9 | 83% | 1% | 5 |
| 2 | MOUSE MODEL SYSTEMS | 6 | 80% | 1% | 4 |
| 3 | FRACTIONATED SCHEDULES | 3 | 38% | 2% | 6 |
| 4 | C3H KM MOUSE | 3 | 42% | 1% | 5 |
| 5 | CONTINUOUS ORGANOTYPIC CULTURE | 2 | 50% | 1% | 3 |
| 6 | CANCER CHEMOTHERAPEUTIC DRUGS | 2 | 36% | 1% | 4 |
| 7 | HYPOXIC CELLS INVITRO | 1 | 100% | 1% | 2 |
| 8 | SOLID TUMOR MODELS | 1 | 50% | 1% | 2 |
| 9 | SLOW RELEASE DEVICES | 1 | 33% | 1% | 3 |
| 10 | LEWIS LUNG TUMOR | 1 | 40% | 1% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| COMBINED TREATMENT OF RADIATION AND CIS-DIAMMINEDICHLOROPLATINUM(II) - A REVIEW OF EXPERIMENTAL AND CLINICAL-DATA | 1987 | 327 | 62 | 56% |
| RADIATION AND PLATINUM DRUG-INTERACTION | 1985 | 89 | 18 | 50% |
| INTERACTIONS OF CHEMOTHERAPY AND RADIATION | 1993 | 36 | 68 | 21% |
| Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters | 2012 | 2 | 86 | 13% |
| RATIONALE FOR DIFFERENT CHEMOTHERAPEUTIC AND RADIATION-THERAPY STRATEGIES IN CANCER MANAGEMENT | 1991 | 23 | 35 | 29% |
| INTERACTIONS BETWEEN ANTITUMOR AGENTS AND RADIATION AND THE EXPRESSION OF RESISTANCE | 1991 | 35 | 138 | 20% |
| EXPERIMENTAL AND CLINICAL-STUDIES ALTERNATING CHEMOTHERAPY AND RADIOTHERAPY | 1989 | 9 | 21 | 33% |
| THE COMBINATION OF RADIOTHERAPY AND CHEMOTHERAPY - A REVIEW | 1989 | 16 | 32 | 22% |
| Combining radiation with oxaliplatin: A review of experimental results | 2008 | 11 | 48 | 10% |
| Nodes Dissections. What's up and what is at stake? | 2014 | 0 | 14 | 14% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SYST THER Y | 0 | 33% | 0.3% | 1 |
| 2 | ONTARIO CANC RADIAT ONCOL | 0 | 25% | 0.3% | 1 |
| 3 | UCLA HEAD NECK CANC PROGRAM | 0 | 25% | 0.3% | 1 |
| 4 | PL RADIAT SCI TECHNOL | 0 | 17% | 0.3% | 1 |
| 5 | RADIOBIOL S | 0 | 14% | 0.3% | 1 |
| 6 | UNITE RADIOBIOL | 0 | 14% | 0.3% | 1 |
| 7 | MED MED RADIOL RADIOBIOL | 0 | 100% | 0.3% | 1 |
| 8 | ONCOLSURG | 0 | 100% | 0.3% | 1 |
| 9 | R HERLEV HOSP | 0 | 100% | 0.3% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000223380 | TCD50//REPOPULATION//R1H RHABDOMYOSARCOMA |
| 2 | 0.0000158341 | CISPLATIN RESISTANCE//PLATINUM DNA ADDUCTS//HUMAN OVARIAN CANCER CELL LINE |
| 3 | 0.0000137737 | HEAD AND NECK CANCER//INDUCTION CHEMOTHERAPY//LOCALLY ADVANCED HEAD AND NECK CANCER |
| 4 | 0.0000135209 | STAGE III//LOCALLY ADVANCED NON SMALL CELL LUNG CANCER//ACUTE ESOPHAGITIS |
| 5 | 0.0000114037 | LOW DOSE HYPER RADIOSENSITIVITY//HYPER RADIOSENSITIVITY//ULTRAFRACTIONATION |
| 6 | 0.0000097941 | RADIATION MYELOPATHY//LINEAR QUADRATIC MODEL//EXPT ZENTRUM |
| 7 | 0.0000085578 | CALVERT FORMULA//CHATELUT FORMULA//SKI 2053R |
| 8 | 0.0000085289 | MED MEANS CHEM//EMIZCO//P NITROACETOPHENONE |
| 9 | 0.0000084704 | LIPOSOMAL CISPLATIN//LIPOPLATIN//SPI 077 |
| 10 | 0.0000073653 | LONG LIVED RADICAL//LONG LIVED RADICALS LLR//HUMAN ECOL ENVIRONM HYG |